Agenda | Speaker |
---|---|
Welcome and Introduction | Roman Hájek (Ostrava, Czechia) |
Identifying the Risk of Infections in Multiple Myeloma – Impact of Disease, Treatment and Supportive Care | Roman Hájek (Ostrava, Czechia) |
Bispecific Antibodies and CAR T Cells – Handling the Infection Risk Related to their Use | Ajai Chari (San Francisco, USA) |
Reducing Infections – Recommendations, Guidelines and Perspectives | Roberto Ria (Bari, Italy) |
Clinical Data on the Use of Intravenous or Subcutaneous Immunoglobulins | Luc Mouthon (Paris, France) |
Interactive Panel Discussion: Challenging Cases Involving Infections Associated with Multiple Myeloma | All Faculty |
Closing Remarks | Roman Hájek (Ostrava, Czechia) |
EHA2024
Octapharma Hybrid Update-in-Hematology
Multiple Myeloma and Beyond: Management of the Infection Burden
Friday, June 14, 2024
16:15 - 17:45 CEST
Hall N103 | IFEMA, Madrid
In recent years, survival rates for patients with multiple myeloma have improved. However, the clinical setting varies greatly among patients, and infections remain a significant concern. The session will begin with an introduction and a discussion on the risk of infections in multiple myeloma patients, considering the disease itself, the treatments administered, and the supportive care provided.
The use of bispecific antibodies and CAR T cells in the treatment of multiple myeloma has shown promise. However, these treatments come with their own risks, including the risk of infection. This topic will be explored in depth, providing valuable insights into managing these risks.
Strategies to minimize infections in multiple myeloma patients will be discussed next, providing recommendations and guidelines, as well as sharing perspectives on the future of infection management. This will be followed by a presentation on clinical data related to the use of intravenous or subcutaneous immunoglobulins in multiple myeloma patients.
The session will conclude with an interactive panel discussion involving all faculty members, where they will discuss challenging cases of infections associated with multiple myeloma. This will provide an opportunity for the audience to engage in the discussion. Questions from the audience will be answered at the end of the session.
Symposium programme
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.
Meet the speakers
Roman Hájek
University Hospital Ostrava and University of Ostrava
Ostrava, Czechia
Ajai Chari
University of California
San Francisco, USA
Roberto Ria
University of Bari
Bari, Italy
Luc Mouthon
University Hospital Cochin
Paris, France
To attend this Hybrid Update-in-Hematology, register to the EHA2024 Hybrid Congress.
Access materials on Science Hub
Can't join us at EHA2024? Access the materials on-demand on Science Hub, our educational platform for healthcare professionals.